Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia
Status:
Completed
Trial end date:
2019-11-27
Target enrollment:
Participant gender:
Summary
To describe the safety and tolerability of evolocumab in participants with homozygous
familial hypercholesterolemia (HoFH) in India. All participants will receive evolocumab over
an 8-week period.